Proceedings of the 3rd International Conference on Modern Medicine and Global Health
DOI: 10.54254/2753-8818/98/2025.21470

Advances in Hematopoietic Stem Cell Research and Their Applications in Disease Therapy

Xinyu Hu[1,a,*]

[1]*Dehong Shanghai International Chinese School, Shanghai, 201100, China*
a. cindyhuxinyu@hotmail.com
**corresponding author*

Abstract: Hematopoietic stem cells (HSCs) serve a critical role in maintaining the immune system and hematological homeostasis. Through their unique capacity for both self-renewal and multilineage differentiation, HSCs give rise to all blood cell types. The dysregulation of HSC function is closely linked to the pathogenesis of various hematologic disorders. Thus, this paper examines the role of HSCs in acute lymphoblastic leukemia, sickle cell disease, and aplastic anemia, highlighting their significance in disease development and therapeutic approaches. Furthermore, current therapeutic strategies, including cell transplantation and gene editing techniques, are reviewed by analyzing relevant literature, and their advantages, limitations and future directions of these approaches are discussed. The results suggest that despite the progress made in current therapeutic approaches, challenges persist, especially in terms of immune rejection and durability of treatment response. These issues hinder the long-term effectiveness of therapies, as immune resistance can cause graft failure or relapse, and the durability of therapeutic benefits remains a major concern for patient outcomes. As such, future research should optimize treatment options, overcome the limitations of current technologies, and enhance clinical outcomes.

Keywords: Hematopoietic Stem Cell (HSC), Acute Lymphocytic Leukemia, Sickle Cell Disease, Aplastic Anemia, Cancer Treatment

1. Introduction

Hematopoietic stem cells (HSC) are an important component of the blood system, responsible for the production of various blood cell types, including red blood cells, white blood cells, and platelets. In recent years, significant progress has been made in the research on HSCs, driven by advances in molecular biology and cell biology techniques. The dysfunction of HSCs is closely related to the development of many serious diseases, such as malignancies, immune system disorders, as well as hematologic disorders. Understanding the biological properties of HSCs and their mechanisms of action in diseases is essential for developing effective therapeutic strategies. The clinical application of HSCs has yielded remarkable success, especially in the treatment of hematologic diseases, where stem cell transplantation has become a standard therapeutic approach. In addition, the development of gene editing technology has provided new possibilities for the treatment of HSCs, especially in the treatment of some hereditary blood disorders, showing substantial potential. However, existing treatments face certain challenges, such as immune rejection, long-term effects of cell transplantation, and treatment costs, which necessitate further research and technological innovation to overcome.

DOI: 10.54254/2753-8818/98/2025.21470

The paper seeks to explore the functions and mechanisms of HSCs, focusing on the role of HSCs in acute lymphoblastic leukemia, sickle cell disease, and aplastic anemia. Moreover, it reviews current cancer therapies and analyzes the strengths and weaknesses of various treatment options, offering new perspectives and directions for future research and clinical interventions.

2. Overview of Hematopoietic Stem Cells and Related Disorders

2.1. Basics of Hematopoietic Stem Cells

HSCs are mainly found in the bone marrow and have the ability to self-renew and differentiate into a variety of blood cells (e.g., erythrocytes, leukocytes, and platelets) [1]. The developmental process of HSCs is closely related to the formation and maintenance of the human hematopoietic system. The generation and differentiation of HSCs can meet the body's demand for various types of blood cells, ensuring the normal function of the blood system. As a key component of the immune system and hematopoietic system, HSC dysfunction leads to a decline in system function, which triggers a series of inflammatory reactions and blood-related diseases [2]. In addition, HSCs play a key role in the construction and maintenance of the bone marrow microenvironment (BMM). In response to external stimuli, HSCs rapidly activate a small number of cells, hence promoting differentiation and maintaining hematopoietic homeostasis within the body [3]. Related research shows that in every 10,000 bone marrow cells, only about one is a HSC [4].

2.2. HSC-Related Diseases

HSCs regulate hematopoietic cell differentiation, making them critical for treating many illnesses. They are not only involved in the renewal and regeneration of normal blood cells, but are pivotal in the treatment of malignancies, hematological disorders, and certain liver diseases [5]. In particular, leukemia, some malignant solid tumors, aplastic anemia, severe immunodeficiency diseases, and acute radiation sickness have all been treated with HSC transplantation [1]. Advances in molecular biology have led to a resurgence of interest in HSC-based gene therapy, with researchers reporting encouraging results. For instance, it has been successfully applied in the treatment of genetic blood disorders, such as Fanconi anemia, and β-thalassemia [6]. The relationship between HSCs and diseases such as acute lymphoblastic leukemia (ALL), sickle cell anemia and aplastic anemia will be explored in depth.

2.2.1. Acute Lymphocytic Leukemia

Acute lymphoblastic leukemia (ALL) is caused by the overproduction of lymphocytes in the bone marrow. The differentiation of HSCs into lymphoid cells occurs through several steps: HSCs first differentiate into lymphoid stem cells, which then become lymphoblasts. If this process is abnormal, the overpopulated lymphoblasts can transform into leukemia cells, ultimately impairing the function of healthy blood cells, such as red and white blood cells. In addition, risk factors for ALL include smoking, genetic factors, and direct risk factors such as age. In addition, radiation exposure is an important indirect risk factor for ALL, and radiation may contribute to the emergence of leukemia cells by altering the differentiation process of HSC. And the prognosis of ALL is influenced by a variety of factors, mainly including the patient's age, genetic mutations, as well as the distribution of leukemia cells [7].

2.2.2. Sickle Cell Anemia

Sickle cell anemia is an inherited disorder resulting from a mutation in the hemoglobin gene. The mutated hemoglobin molecules result in the rigidity of red blood cells, leading to a sickle-shaped

DOI: 10.54254/2753-8818/98/2025.21470

morphology. The morphological alteration leads to reduced flexibility in red blood cells, enhancing their propensity to adhere to vascular walls, thereby obstructing blood flow and precipitating pain crises. The destruction rate of sickle cells is sevenfold greater than that of normal red blood cells, resulting in a markedly reduced lifespan. And the limitations of HSCs in producing new blood cells result in the ongoing depletion of sickle cells, which causes anemia. From the perspective of HSCs, the pathological mechanism of sickle cell anemia is closely related to HSC dysfunction. Normally, HSCs generate various types of blood cells through self-renewal and differentiation. However, in sickle cell anemia, mutated HSCs produce red blood cells that carry abnormal hemoglobin, which alters their shape and function, resulting in the accumulation of sickle-shaped red blood cells in circulation. These abnormal red blood cells not only exacerbate anemia symptoms but also trigger various complications, such as organ damage and thrombosis [8].

2.2.3. Aplastic Anemia

Aplastic anemia is a severe disease caused by the inability of HSCs to effectively produce sufficient blood cells. The core mechanism involves damage to the quantity or functionality of HSCs, leading to bone marrow failure and subsequently impairing the normal functioning of the hematopoietic and immune systems. A reduction in red blood cells results in inadequate oxygen transport, leading to symptoms of anemia, while a decrease in white blood cells significantly weakens the immune system, heightening susceptibility to infections. Also, aplastic anemia can occur at any age but is more common in adolescents and the elderly. Its etiology is diverse, encompassing genetic factors, immune system disorders, radiation exposure, and contact with harmful chemicals. And these factors can directly harm HSCs or modify their microenvironment, inhibiting the self-renewal and differentiation capabilities of HSCs, which leads to a complete failure in blood cell production. Common treatments include blood transfusions, medications (such as antibiotics) to promote blood cell production. In addition, HSC and bone marrow transplantation are effective therapeutic routes to help patients return to normal blood cell production [9].

3. Existing Treatment Methods for HSCs

3.1. Traditional and Emerging Treatment Methods

Existing treatments include traditional approaches like chemotherapy and radiation therapy, as well as emerging methods such as targeted therapy, immunotherapy, and cell transplantation, each of which has its own strengths and limitations in treating hematological diseases.

Chemotherapy is a commonly used treatment for cancer, effectively controlling tumor growth by targeting rapidly dividing cancer cells. However, chemotherapy drugs can also damage healthy cells that divide quickly, thereby leading to side effects such as immune suppression and hair loss[10]. This treatment is typically administered through oral or intravenous medications, which work by disrupting the DNA replication and cell division processes in cancer cells. Radiation therapy is a treatment method that delivers high-energy radiation to specific areas of the body using specialized equipment, aiming to inhibit the growth of cancer cells. It is highly effective in treating localized cancers, especially when the tumor is confined to a specific area. However, radiation therapy can also cause side effects, including damage to surrounding healthy tissues and an increased risk of developing secondary cancers [10]. The treatment generally depends on accurate radiation dosages to reduce the effects on healthy tissues.

In addition, targeted therapy works selectively on specific cancer cells through drugs. Targeted therapy, in contrast to conventional chemotherapy, specifically targets cancer cells, minimizing harm to normal cells. For example, in the treatment of (ALL, tyrosine kinase inhibitors can be used to inhibit the activity of tyrosine kinase, affecting the production of leukemia cells and thus reducing the differentiation of HSCs [11]. Meanwhile, BCL2 inhibitors block the function of BCL2 protein and induce leukemia cell death, thus treating ALL [11]. Monoclonal antibody therapy utilizes laboratory-synthesized antibody proteins to specifically kill targeted cancer cells. This treatment is highly precise and has fewer side effects, but it is costly and may have some effect on non-targeted cells [12]. Immunotherapy enhances the patient's immune system with laboratory-synthesized substances that enable them to fight cancer more effectively. For example, Lenalidomide acts as an immunomodulator that helps kill cancer cells by stimulating T-cell activity [13]. Moreover, CAR T-cell therapy offers new hope for cancer treatment by modifying T-cells so that they can recognize and kill cancer cells, a treatment that offers new hope for cancer treatment [13]. Cell transplantation is a method used to treat certain hematopoietic diseases such as lymphoma, leukemia, multiple myeloma, systemic lupus erythematosus, aplastic anemia, sickle cell disease, and multiple sclerosis [14].HSC transplantation can help patients rebuild their hematopoietic system, regulate the function of the HSC, and restore normal cellular differentiation and function. Although HSC transplantation has been widely used worldwide, its challenges include the need to ensure that there is a matching HLA type between donor and recipient, otherwise it may lead to immune rejection and the risk of disease relapse. When cell transplantation is performed, chemotherapy may kill healthy stem cells, resulting in insufficient HSC. To ensure therapeutic efficacy, some patients' or donors' HSC can be extracted before chemotherapy and reimplanted into patients by injection after chemotherapy to support cell differentiation and hematopoietic recovery [14].

3.2. Efficacy and Limitations of Each Method

Each treatment method has different effects and limitations in different situations, and patients need to choose the appropriate treatment according to the type of disease and their own conditions.

Chemotherapy acts on cancer cells through a variety of ways, but it also has more significant side effects, which not only kills cancer cells, but may also harm healthy cells, leading to adverse reactions such as decreased immune function, nausea, and hair loss [10]. Radiation therapy is effective in treating localized cancers, but its side effects include damage to normal tissues such as skin damage, fatigue and possible risk of secondary cancers [10]. Therefore, the use of radiation therapy needs to be precisely controlled to minimize the impact on healthy tissues. Targeted therapy offers reduced side effects and enhanced therapeutic precision, which is more cost-effective and convenient than conventional chemotherapy. However, the effects of targeted drugs are affected by individual patient differences and metabolic capacity, and the therapeutic effect may be limited, especially in the presence of drug resistance [11]. Monoclonal antibody therapy has a lower risk and higher response rate to accurately target cancer cells. Despite its fewer side effects, the treatment is costly and may trigger an immune response that affects the normal function of other cells [12]. Cell therapy, as an emerging treatment, has greater potential, but it is more costly and may bring about immune rejection or other side effects. Cell therapy still needs further research and development to improve its efficacy and safety [13]. Cell transplantation has significant advantages in the treatment of hematopoietic disorders and can address the lack of HSC and misdifferentiation. Nevertheless, patients may experience immune rejection, which poses a challenge to therapeutic efficacy. Thus, improving HSC matching and reducing rejection are the focus of future research [14].

4. Strategies for Future Research

4.1. Forward Position and Potential Application

HSCs hold significant potential in disease treatment due to their essential role in cell differentiation, which is crucial for maintaining normal hematopoietic function. Abnormal differentiation can lead to hematopoietic disorders, providing valuable insights for their treatment. Improving categorization methods to make research and therapeutic applications more accurate has been the focus of recent investigations. The genetic features of various cell types inside the bone marrow niche have been better understood thanks to advances in molecular technologies, especially high-resolution bone marrow mapping, which has allowed for more accurate identification and categorization [13]. It is also important to note that HSCs can be classified based on markers. Different HSCs may exhibit distinct responses after immune stimulation. For instance, CD317 and CD69 have been identified as new markers for HSCs after immune stimulation, contributing to improved HSC classification [14]. In clinical applications, obtaining HSCs from peripheral blood is challenging due to their low abundance. The discovery of granulocyte colony-stimulating factor (gCSF) has provided a solution to this problem by promoting the replication of HSCs, increasing their concentration in peripheral blood, and making them available for extraction and transplantation [15].

4.2. Key Challenges and Possible Solutions

Investigating HSCs and their therapeutic applications requires a long-term commitment, frequently extending over multiple decades. The prolonged duration poses a considerable obstacle to continued research advancement. Exploring the full potential of HSCs involves overcoming several challenges, including high research costs, technological limitations, and undiscovered mechanisms. As rapidly developing fields, CRISPR gene editing and synthetic biology not only accelerate functional gene analysis but may also play a key role in regulating hematopoietic differentiation, thereby offering potential solutions to these issues [4]. Besides, reducing immune restrictions and rejection reactions in HSC transplantation is a key challenge. This issue may be addressed using HSC regulators and gene editing techniques, which could improve transplant outcomes by minimizing immune rejection [4]. Despite numerous studies believing that HSCs possess the ability for infinite self-renewal without undergoing the aging process characteristic of other cells, it remains highly controversial. Therefore, further exploration of the origin, development, differentiation, and other characteristics of HSCs is essential. Targeted gene therapies and treatments for hematopoietic and immunological illnesses can be made possible with a better knowledge of the differentiation process [16]. The classification of hematopoietic differentiation is also a significant challenge. By studying the origins of hematopoietic diseases and cancers, the timing of cell differentiation, the activity of different stem cells, and the boundaries between stem and progenitor cells, it will be possible to provide more effective treatments for these diseases [17].

5. Conclusion

This review highlights the critical role of HSCs in the treatment of blood disorders, particularly in diseases such as acute lymphoblastic leukemia, sickle cell anemia, and aplastic anemia. Research indicates that HSC transplantation and gene editing technologies offer new therapeutic prospects for many hematologic diseases. However, immune rejection and the durability of treatment outcomes remain major challenges in current therapies. Although this paper explores existing treatment methods and future research directions, the complexity of the involved strategies and technologies means that the long-term effects and safety of emerging techniques such as gene editing and cell therapy are not yet fully understood. Furthermore, the classification of different types of HSCs and the development of refined therapeutic strategies are still in the research phase, with the diversity of studies and reproducibility of results requiring further validation. Future research should focus on overcoming the limitations of current treatment approaches, particularly issues related to immune rejection, treatment durability, and cost. With advances in molecular techniques and gene editing, researchers are expected to better classify and understand different types of HSCs, laying the foundation for precision therapies. Enhancing the success rate of HSC transplantation through novel

DOI: 10.54254/2753-8818/98/2025.21470

biomarkers and regulatory factors, reducing side effects, and developing more cost-effective treatment options will be key areas of focus in future studies.

References

[1] Red Cross Society of China. (2019) Hematopoietic Stem Cells: An Overview. https://www.redcross.org.cn/html/2019-05/60050.html

[2] Kumar, A., D'Souza, S.S. and Thakur, A.S. (2019) Understanding the Journey of Human Hematopoietic Stem Cell Development. Stem Cells International, 1-13.

[3] Hao, S., Wang, Y., Dong, F. and Cheng, T. (2015) Crosstalk between hematopoietic stem cells and immune system. Zhonghua Xue Ye Xue Za Zhi, 36(12): 1043-1048

[4] Ng, A.P. and Alexander, W.S. (2017) Haematopoietic Stem cells: past, Present and Future. Cell Death Discovery. 3: 17002.

[5] Lee, J.Y. and Hong, S.H. (2019) Hematopoietic Stem Cells and Their Roles in Tissue Regeneration. International Journal of Stem Cells, 13(1).

[6] Li, Q., Hao, S. and Cheng, T. (2022) Research progress on in vitro expansion and clinical application of hematopoietic stem cell. Zhonghua Xue Ye Xue Za Zhi, 43(2): 167-172.

[7] PDQ Adult Treatment Editorial Board. (2024) Acute Lymphoblastic Leukemia Treatment (PDQ®): Patient Version. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute.

[8] National Heart, Lung and Blood Institute. (2022) Sickle Cell Disease - Causes and Risk Factors. https://www.nhlbi.nih.gov/health/sickle-cell-disease/causes.

[9] Johns Hopkins Medicine. (2024) Aplastic Anemia. https://www.hopkinsmedicine.org/health/conditions-and-diseases/aplastic-anemia.

[10] Moawad, H. (2024) What to Expect From Hematopoietic Stem Cell Transplantation. Verywell Health. https://www.verywellhealth.com/hematopoietic-stem-cell-transplantation-5205381

[11] Wang, Y. and Huang, X.J. (2019) Progress of hematopoietic stem cell transplantation in hematologic diseases. Chinese Journal of Hematology, 40(8): 704-708.

[12] Liu, B., et al. (2024) Exploring treatment options in cancer: Tumor treatment strategies. Signal Transduction and Targeted Therapy, 9(1): 1-44.

[13] Pinho, S. and Frenette, P.S. (2019) Haematopoietic stem cell activity and interactions with the niche. Nature Reviews Molecular Cell Biology, 20(5): 303-320.

[14] Bujanover, N., et al. (2018) Identification of immune-activated hematopoietic stem cells. Leukemia, 32(9): 2016-2020.

[15] Skulimowska, I., et al. (2021) The biology of hematopoietic stem cells and its clinical implications. The FEBS Journal, 289(24): 7740-7759.

[16] Mosaad, Y.M. (2014) Hematopoietic stem cells: An overview. Transfusion and Apheresis Science. 51(3):68-82.

[17] Laurenti, E. and Göttgens, B. (2018) From haematopoietic stem cells to complex differentiation landscapes. Nature, 553(7689): 418-426.